Illumina (ILMN) : Bourne Lent Asset Management Inc has sold out all of its stake in Illumina during the most recent quarter, according to the disclosure filed by the company on Jul 26, 2016 with the SEC. The investment management company has sold out 1,400 shares of Illumina which is valued at $227,150.
Other Hedge Funds, Including , Calamos Advisors boosted its stake in ILMN in the latest quarter, The investment management firm added 4,197 additional shares and now holds a total of 65,212 shares of Illumina which is valued at $10,580,647. Illumina makes up approx 0.10% of Calamos Advisors’s portfolio.Douglas Lane Associates boosted its stake in ILMN in the latest quarter, The investment management firm added 13,639 additional shares and now holds a total of 441,993 shares of Illumina which is valued at $71,713,364. Illumina makes up approx 1.95% of Douglas Lane Associates’s portfolio.Biondo Investment Advisors boosted its stake in ILMN in the latest quarter, The investment management firm added 540 additional shares and now holds a total of 32,136 shares of Illumina which is valued at $4,844,823. Illumina makes up approx 1.66% of Biondo Investment Advisors’s portfolio. Independent Portfolio Consultants sold out all of its stake in ILMN during the most recent quarter. The investment firm sold 365 shares of ILMN which is valued $54,593.
Illumina closed down -0.07 points or -0.04% at $166.35 with 12,17,434 shares getting traded on Friday. Post opening the session at $165.97, the shares hit an intraday low of $163.11 and an intraday high of $166.6299 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Illumina reported $0.71 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on May 3, 2016. Analyst had a consensus of $0.74. The company had revenue of $571.80 million for the quarter, compared to analysts expectations of $580.44 million. The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.91 EPS.
Many Wall Street Analysts have commented on Illumina. Company shares were Reiterated by Mizuho on Jul 27, 2016 to “Neutral”, Firm has raised the Price Target to $ 148 from a previous price target of $138 .Shares were Downgraded by Morgan Stanley on Jul 5, 2016 to ” Underweight” and Lowered the Price Target to $ 110 from a previous price target of $130 .Illumina was Initiated by CL King to “Buy” on Jun 22, 2016.
Illumina Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms reagent kits and scanning equipment. Its customers include genomic research centers academic institutions government laboratories hospitals and reference laboratories pharmaceutical biotechnology agrigenomics commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research including de novo sequencing genetic variation analysis epigenetics and targeted screening among others. It also provides products and services for other life sciences applied markets such as agrigenomics. It also offers Clarity Run Manager Clarity LIMS Silver and Clarity LIMS Gold.